OPTimizing Adjuvant Prescription of PEMBROlizumab in Patients With Early-stage Triple-negative Breast Cancer Achieving Pathologic Complete Response After Standard Neoadjuvant Chemotherapy and Pembrolizumab
Latest Information Update: 30 Sep 2024
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Early breast cancer; HER2 negative breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms OPT-PEMBRO
- 30 Sep 2024 New trial record